Gliknik Inc.

14 patents currently held · Updated Nov 14, 2026

3 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

May 2028

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Apr 24, 2027
The maintenance fee for Manufacturing optimization of GL-2045, a multimerizing stradomer (US 11,795,193) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 9,926,362	Immunoglobulin Constant Region FC Receptor Binding Agents In force Term ends May 30, 2028 · High confidence	In force	Term ends May 30, 2028	High confidence
US 10,941,191	Immunoglobulin Constant Region FC Receptor Binding Agents In force Term ends May 30, 2028 · High confidence	In force	Term ends May 30, 2028	High confidence
US 9,512,208	Immunoglobulin Constant Region FC Receptor Binding Agents In force Term ends Apr 10, 2029 · High confidence	In force	Term ends Apr 10, 2029	High confidence
US 8,680,237	Immunoglobulin Constant Region FC Receptor Binding Agents In force Term ends Aug 26, 2030 · High confidence	In force	Term ends Aug 26, 2030	High confidence
US 11,117,940	FUSION PROTEINS OF NATURAL HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN Fc COMPOSITIONS In force Term ends Apr 15, 2032 · High confidence	In force	Term ends Apr 15, 2032	High confidence
US 12,084,482	FUSION PROTEINS OF NATURAL HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN Fc COMPOSITIONS In force Term ends Mar 22, 2033 · High confidence	In force	Term ends Mar 22, 2033	High confidence
US 9,683,044	Molecules with antigen binding and polyvalent FC gamma receptor binding activity In force Term ends Feb 17, 2035 · From the USPTO record	In force	Term ends Feb 17, 2035	From the USPTO record
US 11,034,775	Cysteine-optimized stradomers In force Term ends Jun 7, 2037 · From the USPTO record	In force	Term ends Jun 7, 2037	From the USPTO record
US 12,122,836	Fusion Proteins of Human Protein Fragments to Create Orderly Multimerized Immunoglobulin FC Compositions with Enhanced Complement Binding In force Term ends Dec 1, 2037 · Medium confidence	In force	Term ends Dec 1, 2037	Medium confidence
US 11,795,193	Manufacturing optimization of GL-2045, a multimerizing stradomer In force Term ends Dec 8, 2037 · From the USPTO record	In force	Term ends Dec 8, 2037	From the USPTO record

10 of 14 patents shown.

Pro members see all 14.

Pro members: see all 14 patents

Also on record, not counted in the 14: 3 patents in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending · 9 abandoned · 4 no status recorded

List them